Press Release · Immorta Bio, Inc
Immorta Bio Demonstrates "Serial Killing" of Senescent Cells by SenoMune™-0257-Stimulated T Cells
Distributed by Mini Business News · Originally issued via PR Newswire

Laboratory studies observed a single CD8+ T cell eliminate up to 11 senescent cells, with no detectable activity against tested non-senescent controls
MIAMI, Nov. 20, 2026 — Immorta Bio, Inc., a clinical-stage biotechnology company developing therapies to restore youthful biology, today announced new laboratory findings involving SenoMune™-0257, its investigational nine-amino-acid senolytic peptide immunotherapy. In these experiments, peptide-stimulated CD8+ T cells repeatedly eliminated senescent cells; an individual T cell was observed killing up to 11 senescent target cells in succession, an immune mechanism known as "serial killing."
The findings highlight two important properties for the development of potent senolytic peptide immunotherapy: the ability of an activated T cell to kill senescent targets repeatedly, and selectivity for senescent cells over the non-senescent controls tested. The experiments were conducted in vitro. SenoMune™-0257 has also entered human clinical evaluation, where investigators will assess its biological activity, including whether—and to what degree—it reduces senescent-cell burden in patients.
Senescent cells, sometimes called "zombie cells," accumulate with age and can contribute to chronic inflammation, tissue damage, and a range of age-related diseases. Immorta Bio is developing SenoMune™-0257 as a potent senolytic immunotherapy aimed at reducing this harmful cellular burden. The broader objective is to restore youthful biology and use it as a therapeutic engine for treating diseases of aging and, ultimately, aging itself.
"What stands out is the combination of potency and selectivity: in our laboratory experiments, a single CD8+ T cell repeatedly eliminated senescent targets while the non-senescent controls tested were spared," said Thomas E. Ichim, PhD, President and Chief Scientific Officer of Immorta Bio. "We have now moved SenoMune™-0257 into a pilot human study. An important focus is to determine whether the peptide reduces senescent-cell burden in patients, and how substantial that reduction may be."
The new SenoMune™-0257 findings build on Immorta Bio's published research into senolytic immunotherapy and offer additional mechanistic evidence supporting the company's strategy of clearing harmful senescent cells as a means of restoring youthful biology.
Human clinical evaluation of SenoMune™-0257 began on October 29, 2026, in an independent investigator-initiated pilot study in Mexico involving up to six patients with advanced cancer. The study is evaluating safety and seeking preliminary evidence of the peptide's biological activity, including whether—and to what extent—SenoMune™-0257 reduces senescent-cell burden in humans. The new laboratory findings and the ongoing human study represent complementary steps in the company's clinical development program.
"Restoring youthful biology is the central mission of Immorta Bio," said Boris N. Reznik, PhD, Chairman and CEO. "Clearing harmful senescent cells is one of our two fundamental therapeutic approaches, alongside restoring regenerative capacity through StemCellRevivify™. The ability of SenoMune™-0257–stimulated immune cells to repeatedly eliminate senescent cells in the laboratory is particularly exciting as we advance our first clinical evaluation and pursue a broader therapeutic engine for diseases of aging."
Scientific background
Ichim TE et al. "Reduction of solid tumors by senescent cell immunization." Journal of Translational Medicine (2025). https://pmc.ncbi.nlm.nih.gov/articles/PMC12661736/. This publication concerns earlier preclinical senolytic-immunotherapy research, not the newly reported serial-killing experiment.
Media Contact
Boris N. Reznik, PhD | Chairman & CEO
Immorta Bio, Inc.
[email protected] | 305-632-2939
immortabio.com
SOURCE Immorta Bio, Inc
About Immorta Bio
Immorta Bio, Inc. is developing two complementary therapeutic platforms aimed at fundamental drivers of aging: SenoMune™, designed for immune-mediated clearance of senescent cells, and StemCellRevivify™, focused on restoring youthful regenerative capacity. Together, the platforms support the company's strategy of "Restoring Youthful Biology as a Therapeutic Engine" and its mission of "Treating Diseases of Aging and Treating Aging as Disease™."